1 Module 1 Administrative information
1.1 Forms [Form Type (R)]
1.2 Cover letters
1.3 Administrative information
1.3.1 Contact/sponsor/applicant information
1.3.1.1 Change of address or corporate name
1.3.1.2 Change in contact/agent
1.3.1.3 Change in sponsor
1.3.1.4 Transfer of obligation
1.3.1.5 Change in ownership of an application or reissuance of license
1.3.2 Field copy certification
1.3.3 Debarment certification
1.3.4 Financial certification and disclosure
1.3.5 Patent and exclusivity
1.3.5.1 Patent information
1.3.5.2 Patent certification
1.3.5.3 Exclusivity claim
1.3.6 Tropical disease priority review voucher
1.4 References
1.4.1 Letter of authorization
1.4.2 Statement of right of reference
1.4.3 List of authorized persons to incorporate by reference
1.4.4 Cross-reference to previously submitted information
1.5 Application status
1.5.1 Withdrawal of an IND
1.5.2 Inactivation request
1.5.3 Reactivation request
1.5.4 Reinstatement request
1.5.5 Withdrawal of an unapproved BLA, NDA, ANDA, or Supplement
1.5.6 Withdrawal of listed drug
1.5.7 Withdrawal of approval of an application or revocation of license
1.6 Meetings
1.6.1 Meeting request
1.6.2 Meeting background materials
1.6.3 Correspondence regarding meetings
1.7 Fast Track
1.7.1 Fast track designation request
1.7.2 Fast track designation withdrawal request
1.7.3 Rolling review request
1.7.4 Correspondence regarding fast track/rolling review
1.8 Special protocol assessment request
1.8.1 Clinical study
1.8.2 Carcinogenicity study
1.8.3 Stability study
1.8.4 Animal efficacy study for approval under the animal rule
1.9 Pediatric administrative information
1.9.1 Request for waiver of pediatric studies
1.9.2 Request for deferral of pediatric studies
1.9.3 Request for pediatric exclusivity determination
1.9.4 Proposed pediatric study request and amendments
1.9.6 Other correspondence regarding pediatric exclusivity or study plans
1.10 Dispute resolution
1.10.1 Request for dispute resolution
1.10.2 Correspondence related to dispute resolution
1.11 Information amendment: Information not covered under modules 2 to 5
1.11.1 Quality information amendment
1.11.2 Nonclinical information amendment
1.11.3 Clinical information amendment
1.11.4 Multiple module information amendment
1.12 Other correspondence
1.12.1 Pre IND correspondence
1.12.2 Request to charge for clinical trial
1.12.3 Request to charge for expanded access
1.12.4 Request for comments and advice
1.12.5 Request for a waiver
1.12.6 Exception from informed consent for emergency research
1.12.7 Public disclosure statement for exception from informed consent for emergency research
1.12.8 Correspondence regarding exception from informed consent for emergency research
1.12.9 Notification of discontinuation of clinical trial
1.12.10 Generic drug enforcement act statement
1.12.11 ANDA basis for submission statement
1.12.12 Comparison of generic drug and reference listed drug
1.12.13 Request for waiver for in vivo studies
1.12.14 Environmental analysis
1.12.15 Request for waiver of in vivo bioavailability studies
1.12.16 Field alert reports
1.12.17 Orphan drug designation
1.12.18 Regenerative medicine advanced therapy (RMAT) designation
1.13 Annual report
1.13.1 Summary for nonclinical studies
1.13.2 Summary of clinical pharmacology information
1.13.3 Summary of safety information
1.13.4 Summary of labeling changes
1.13.5 Summary of manufacturing changes
1.13.6 Summary of microbiological changes
1.13.7 Summary of other significant new information
1.13.8 Individual study information
1.13.9 General investigational plan
1.13.10 Foreign marketing
1.13.11 Distribution data
1.13.12 Status of postmarketing study commitments and requirements
1.13.13 Status of other postmarketing studies and requirements
1.13.14 Log of outstanding regulatory business
1.13.15 Development safety update report (DSUR)
1.14 Labeling
1.14.1 Draft labeling
1.14.1.1 Draft carton and container labels
1.14.1.2 Annotated draft labeling text
1.14.1.3 Draft labeling text
1.14.1.4 Label comprehension studies
1.14.1.5 Labeling history
1.14.2 Final labeling
1.14.2.1 Final carton or container labels
1.14.2.2 Final package insert (package inserts, patient information, medication guides)
1.14.2.3 Final labeling text
1.14.3 Listed drug labeling
1.14.3.1 Annotated comparison with listed drug
1.14.3.2 Approved labeling text for listed drug
1.14.3.3 Labeling text for reference listed drug
1.14.4 Investigational drug labeling
1.14.4.1 Investigational brochure
1.14.4.2 Investigational drug labeling
1.14.5 Foreign labeling
1.14.6 Product labeling for 2253 submissions
1.15 Promotional material [promotional-material-audience-type (R)]
1.15.1 Correspondence relating to promotional materials
1.15.1.1 Request for advisory comments on launch materials
1.15.1.2 Request for advisory comments on non-launch materials
1.15.1.3 Presubmission of launch promotional materials for accelerated approval products
1.15.1.4 Presubmission of non-launch promotional materials for accelerated approval products
1.15.1.5 Pre-dissemination review of television ads
1.15.1.6 Response to untitled letter or warning letter
1.15.1.7 Response to information request
1.15.1.8 Correspondence accompanying materials previously missing or rejected
1.15.1.9 Withdrawal request
1.15.1.10 Submission of annotated references
1.15.1.11 General correspondence
1.15.2 Materials[promotional-material-doc-type (R)]
1.15.2.1 Material [promotional-material-type (R), material-id (R), issue-date(O)]
1.15.2.1.1 Clean version
1.15.2.1.2 Annotated version
1.15.2.1.3 Annotated labeling version
1.15.2.1.4 Annotated references
1.16 Risk management plan
1.16.1 Risk Management (Non-REMS)
1.16.2 Risk Evaluation and Mitigation Strategy (REMS)
1.16.2.1 Final REMS
1.16.2.2 Draft REMS
1.16.2.3 REMS Assessment
1.16.2.4 REMS Assessment Methodology
1.16.2.5 REMS Correspondence
1.16.2.6 REMS Modification History
1.17 Postmarketing studies
1.17.1 Correspondence regarding postmarketing commitments
1.17.2 Correspondence regarding postmarketing requirements
1.18 Naming
1.18.1 Proprietary names
1.18.2 Biological Proper Name Suffix
1.19 Pre-EUA and EUA
1.20 General investigational plan for initial IND
2 Module 2 Summaries
2.2 Introduction to summary
2.3 Quality overall summary
2.3.I Introduction
2.3.S Drug substance [substance (O), manufacturer (O)]
2.3.P Drug product [product (O), dosage form (O)]
2.3.A Appendices
2.3.A.1 Facilities and equipment [facility (O)]
2.3.A.2 Adventitious agents safety evaluation [component (O)]
2.3.A.3 Excipients
2.3.R Regional information
2.4 Nonclinical overview
2.5 Clinical overview
2.6 Nonclinical written and tabulated summaries
2.6.1 Introduction
2.6.2 Pharmacology written summary
2.6.3 Pharmacology tabulated summary
2.6.4 Pharmacokinetic written summary
2.6.5 Pharmacokinetic tabulated summary
2.6.6 Toxicology written summary
2.6.7 Toxicology tabulated summary
2.7 Clinical summary
2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
2.7.2 Summary of Clinical Pharmacology studies
2.7.3 Summary of Clinical Efficacy [indication (R)]
2.7.4 Summary of Clinical Safety
2.7.5 References
2.7.6 Synopses of individual studies
3 Module 3 Quality
3.2 Body of data
3.2.S Drug substance [substance (O), manufacturer (O)]
3.2.S.1 General information
3.2.S.2 Manufacture
3.2.S.2.1 Manufacturer(s)
3.2.S.2.2 Description of Manufacturing Process and Process Controls
3.2.S.2.3 Control of Materials
3.2.S.2.4 Controls of Critical Steps and Intermediates
3.2.S.2.5 Process Validation and/or Evaluation
3.2.S.2.6 Manufacturing Process Development
3.2.S.3 Characterization
3.2.S.3.1 Elucidation of Structure and other Characteristics
3.2.S.3.2 Impurities
3.2.S.4 Control of drug substance
3.2.S.4.1 Specification
3.2.S.4.2 Analytical Procedures
3.2.S.4.3 Validation of Analytical Procedures
3.2.S.4.4 Batch Analyses
3.2.S.4.5 Justification of Specification
3.2.S.5 Reference standards or materials
3.2.S.6 Container closure systems
3.2.S.7 Stability
3.2.S.7.1 Stability Summary and Conclusions
3.2.S.7.2 Post Approval Stability Protocol and Stability Commitment
3.2.S.7.3 Stability Data [descriptor (O)]
3.2.P Drug product [product (O), dosage form (O), manufacturer (O)]
3.2.P.1 Description and composition of the drug product
3.2.P.2 Pharmaceutical development
3.2.P.3 Manufacture
3.2.P.3.1 Manufacturer(s)
3.2.P.3.2 Batch Formula
3.2.P.3.3 Description of Manufacturing Process and Process Controls
3.2.P.3.4 Controls of Critical Steps and Intermediates
3.2.P.3.5 Process Validation and/or Evaluation
3.2.P.4 Control of excipients [excipient (O)]
3.2.P.4.1 Specification(s)
3.2.P.4.2 Analytical Procedures
3.2.P.4.3 Validation of Analytical Procedures
3.2.P.4.4 Justification of Specifications
3.2.P.4.5 Excipients of Human or Animal Origin
3.2.P.4.6 Novel Excipients
3.2.P.5 Control of drug product
3.2.P.5.1 Specification(s)
3.2.P.5.2 Analytical Procedures
3.2.P.5.3 Validation of Analytical Procedures
3.2.P.5.4 Batch Analyses
3.2.P.5.5 Characterization of Impurities
3.2.P.5.6 Justification of Specification(s)
3.2.P.6 Reference standards or materials
3.2.P.7 Container closure system [container (O)]
3.2.P.8 Stability
3.2.P.8.1 Stability Summary and Conclusion
3.2.P.8.2 Postapproval Stability Protocol and Stability Commitment
3.2.P.8.3 Stability Data [descriptor (O)]
3.2.A Appendices
3.2.A.1 Facilities and Equipment [facility (O)]
3.2.A.2 Adventitious agents safety evaluation [component (O)]
3.2.A.3 Novel excipients [excipient (O)]
3.2.R Regional information
3.3 Literature references
4 Module 4 Nonclinical Study Reports
4.2 Study reports
4.2.1 Pharmacology
4.2.1.1 Primary pharmacodynamics
4.2.1.1.pseudo [study id_study title (R)] 
4.2.1.1.pseudo.01 [document type (R)]
4.2.1.1.pseudo.02 Legacy clinical study report
4.2.1.1.pseudo.03 Pre clinical study report
4.2.1.1.pseudo.04 Synopsis
4.2.1.1.pseudo.05 Study report body
4.2.1.1.pseudo.06 Protocol or amendment
4.2.1.1.pseudo.07 Signatures investigators
4.2.1.1.pseudo.08 Audit certificates report
4.2.1.1.pseudo.09 Statistical methods interim analysis plan
4.2.1.1.pseudo.10 Inter-laboratory standardisation methods quality assurance
4.2.1.1.pseudo.11 Publications based on study
4.2.1.1.pseudo.12 Publications referenced in report
4.2.1.1.pseudo.13 Compliance and drug concentration data
4.2.1.1.pseudo.14 Data tabulation
4.2.1.1.pseudo.14.1 Data tabulation dataset legacy
4.2.1.1.pseudo.14.2 Data tabulation dataset send
4.2.1.1.pseudo.14.3 Data tabulation data definition
4.2.1.1.pseudo.15 Data listing data set
4.2.1.1.pseudo.15.1 Data listing dataset
4.2.1.1.pseudo.15.2 Data listing data definition
4.2.1.1.pseudo.16 Analysis datasets
4.2.1.1.pseudo.16.1 Analysis dataset adam
4.2.1.1.pseudo.16.2 Analysis dataset legacy
4.2.1.1.pseudo.16.3 Analysis program
4.2.1.1.pseudo.16.4 Analysis data definition
4.2.1.1.pseudo.17 Safety report
4.2.1.1.pseudo.18 Assay validation
4.2.1.1.pseudo.19 Biomarkers
4.2.1.1.pseudo.20 Data monitoring review committees
4.2.1.1.pseudo.21 Device information
4.2.1.1.pseudo.22 Diagnostic tests
4.2.1.1.pseudo.23 Gene therapy
4.2.1.1.pseudo.24 Pharmacodynamics
4.2.1.1.pseudo.25 Pharmacogenomics
4.2.1.1.pseudo.26 Pharmacokinetics
4.2.1.1.pseudo.27 Stem cells
4.2.1.1.pseudo.28 Antibody
4.2.1.1.pseudo.29 Other data not specified
4.2.1.1.pseudo.30 PK PD relationship
4.2.1.1.pseudo.31 Specialty report
4.2.1.1.pseudo.32 Foreign clinical studies not under ind
4.2.1.2 Secondary pharmacodynamics 
4.2.1.2.pseudo [study id_study title (R)]
4.2.1.2.pseudo.1 [document type (R)]
4.2.1.2.pseudo.2 [see 4.2.1.1]
4.2.1.3 Safety pharmacology 
4.2.1.3.pseudo [study id_study title (R)]
4.2.1.3.pseudo.1 [document type (R)]
4.2.1.3.pseudo.2 [see 4.2.1.1]
4.2.1.4 Pharmacodynamic drug interactions 
4.2.1.4.pseudo [study id_study title (R)]
4.2.1.4.pseudo.1 [document type (R)]
4.2.1.4.pseudo.2 [see 4.2.1.1]
4.2.2 Pharmacokinetics
4.2.2.1 Analytical methods and validation reports 
4.2.2.1.pseudo [study id_study title (R)]
4.2.2.1.pseudo.1 [document type (R)]
4.2.2.1.pseudo.2 [see 4.2.1.1]
4.2.2.2 Absorption 
4.2.2.2.pseudo [study id_study title (R)]
4.2.2.2.pseudo.1 [document type (R)]
4.2.2.2.pseudo.2 [see 4.2.1.1]
4.2.2.3 Distribution 
4.2.2.3.pseudo [study id_study title (R)]
4.2.2.3.pseudo.1 [document type (R)]
4.2.2.3.pseudo.2 [see 4.2.1.1]
4.2.2.4 Metabolism 
4.2.2.4.pseudo [study id_study title (R)]
4.2.2.4.pseudo.1 [document type (R)]
4.2.2.4.pseudo.2 [see 4.2.1.1]
4.2.2.5 Excretion 
4.2.2.5.pseudo [study id_study title (R)]
4.2.2.5.pseudo.1 [document type (R)]
4.2.2.5.pseudo.2 [see 4.2.1.1]
4.2.2.6 Pharmacokinetic drug interactions 
4.2.2.6.pseudo [study id_study title (R)]
4.2.2.6.pseudo.1 [document type (R)]
4.2.2.6.pseudo.2 [see 4.2.1.1]
4.2.2.7 Other pharmacokinetic studies 
4.2.2.7.pseudo [study id_study title (R)]
4.2.2.7.pseudo.1 [document type (R)]
4.2.2.7.pseudo.2 [see 4.2.1.1]
4.2.3 Toxicology
4.2.3.1 Single dose toxicity 
4.2.3.1.pseudo [study id_study title (R) species (R), route of admin (R)]
4.2.3.1.pseudo.1 [document type (R)]
4.2.3.1.pseudo.2 [see 4.2.1.1]
4.2.3.2 Repeat dose toxicity 
4.2.3.2.pseudo [study id_study title (R) species (R), route of admin (R), duration(O)]
4.2.3.2.pseudo.1 [document type (R)]
4.2.3.2.pseudo.2 [see 4.2.1.1]
4.2.3.3 Genotoxicity
4.2.3.3.1 In vitro 
4.2.3.3.1.pseudo [study id_study title (R)]
4.2.3.3.1.pseudo.1 [document type (R)]
4.2.3.3.1.pseudo.2 [see 4.2.1.1]
4.2.3.3.2 In vivo 
4.2.3.3.2.pseudo [study id_study title (R)]
4.2.3.3.2.pseudo.1 [document type (R)]
4.2.3.3.2.pseudo.2 [see 4.2.1.1]
4.2.3.4 Carcinogenicity
4.2.3.4.1 Long term studies 
4.2.3.4.1.pseudo [study id_study title (R), species (R)]
4.2.3.4.1.pseudo.1 [document type (R)]
4.2.3.4.1.pseudo.2 [see 4.2.1.1]
4.2.3.4.2 Short or medium term studies 
4.2.3.4.2.pseudo [study id_study title (R)]
4.2.3.4.2.pseudo.1 [document type (R)]
4.2.3.4.2.pseudo.2 [see 4.2.1.1]
4.2.3.4.3 Other studies 
4.2.3.4.3.pseudo [study id_study title (R)]
4.2.3.4.3.pseudo.1 [document type (R)]
4.2.3.4.3.pseudo.2 [see 4.2.1.1]
4.2.3.5 Reproductive and developmental toxicity
4.2.3.5.1 Fertility and early embryonic development 
4.2.3.5.1.pseudo [study id_study title (R)]
4.2.3.5.1.pseudo.1 [document type (R)]
4.2.3.5.1.pseudo.2 [see 4.2.1.1]
4.2.3.5.2 Embryofetal development 
4.2.3.5.2.pseudo [study id_study title (R)]
4.2.3.5.2.pseudo.1 [document type (R)]
4.2.3.5.2.pseudo.2 [see 4.2.1.1]
4.2.3.5.3 Prenatal and postnatal development, including maternal function 
4.2.3.5.3.pseudo [study id_study title (R)]
4.2.3.5.3.pseudo.1 [document type (R)]
4.2.3.5.3.pseudo.2 [see 4.2.1.1]
4.2.3.5.4 Studies in which the offspring (juvenile animals) are dosed and/or further evaluated 
4.2.3.5.4.pseudo [study id_study title (R)]
4.2.3.5.4.pseudo.1 [document type (R)]
4.2.3.5.4.pseudo.2 [see 4.2.1.1]
4.2.3.6 Local tolerance 
4.2.3.6.pseudo [study id_study title (R)]
4.2.3.6.pseudo.1 [document type (R)]
4.2.3.6.pseudo.2 [see 4.2.1.1]
4.2.3.7 Other toxicity studies
4.2.3.7.1 Antigenicity 
4.2.3.7.1.pseudo [study id_study title (R)]
4.2.3.7.1.pseudo.1 [document type (R)]
4.2.3.7.1.pseudo.2 [see 4.2.1.1]
4.2.3.7.2 Immunotoxicity 
4.2.3.7.2.pseudo [study id_study title (R)]
4.2.3.7.2.pseudo.1 [document type (R)]
4.2.3.7.2.pseudo.2 [see 4.2.1.1]
4.2.3.7.3 Mechanistic studies 
4.2.3.7.3.pseudo [study id_study title (R)]
4.2.3.7.3.pseudo.1 [document type (R)]
4.2.3.7.3.pseudo.2 [see 4.2.1.1]
4.2.3.7.4 Dependence 
4.2.3.7.4.pseudo [study id_study title (R)]
4.2.3.7.4.pseudo.1 [document type (R)]
4.2.3.7.4.pseudo.2 [see 4.2.1.1]
4.2.3.7.5 Metabolites 
4.2.3.7.5.pseudo [study id_study title (R)]
4.2.3.7.5.pseudo.1 [document type (R)]
4.2.3.7.5.pseudo.2 [see 4.2.1.1]
4.2.3.7.6 Impurities 
4.2.3.7.6.pseudo [study id_study title (R)]
4.2.3.7.6.pseudo.1 [document type (R)]
4.2.3.7.6.pseudo.2 [see 4.2.1.1]
4.2.3.7.7 Other 
4.2.3.7.7.pseudo [study id_study title (R)]
4.2.3.7.7.pseudo.1 [document type (R)]
4.2.3.7.7.pseudo.2 [see 4.2.1.1]
4.3 Literature references
5 Module 5 Clinical Study Reports
5.2 Tabular listing of all clinical studies
5.3 Clinical study reports and related information
5.3.1 Reports of biopharmaceutic studies
5.3.1.1 Bioavailability (BA) Study reports and related information
5.3.1.1.pseudo [study id_study title (R)] 
5.3.1.1.pseudo.01 [document type (R)]
5.3.1.1.pseudo.02 Legacy clinical study report
5.3.1.1.pseudo.03 Synopsis (ICH E3, section 2)
5.3.1.1.pseudo.04 Study report body (E3 1, 3 to 15)
5.3.1.1.pseudo.05 Protocol or amendment (E3 16.1.1)
5.3.1.1.pseudo.06 Sample case report form (E3 16.1.2)
5.3.1.1.pseudo.07 IEC-IRB consent form list (E3 16.1.3)
5.3.1.1.pseudo.08 List description investigator site (E3 16.1.4)
5.3.1.1.pseudo.09 Signatures investigators (E3 16.1.5)
5.3.1.1.pseudo.10 List patients with batches (E316.1.6)
5.3.1.1.pseudo.11 Randomisation scheme (E3 16.1.7)
5.3.1.1.pseudo.12 Audit certificates report (E3 16.1.8)
5.3.1.1.pseudo.13 Statistical methods interim analysis plan (E3 16.1.9)
5.3.1.1.pseudo.14 Inter-laboratory standardisation methods quality
5.3.1.1.pseudo.15 assurance (E3 16.1.10)
5.3.1.1.pseudo.16 Publications based on study (E3 16.1.11)
5.3.1.1.pseudo.17 Publications referenced in report (E3 16.1.12)
5.3.1.1.pseudo.18 Discontinued patients (E3 16.2.1)
5.3.1.1.pseudo.19 Protocol deviations (E3 16.2.2)
5.3.1.1.pseudo.20 Patients excluded from efficacy analysis (E3 16.2.3)
5.3.1.1.pseudo.21 Demographic data (E3 16.2.4)
5.3.1.1.pseudo.22 Compliance and drug concentration data (E3 16.2.5)
5.3.1.1.pseudo.23 Individual efficacy response data (E3 16.2.6)
5.3.1.1.pseudo.24 Adverse event listings (E3 16.2.7)
5.3.1.1.pseudo.25 Listing individual laboratory measurements by patient (E3 16.2.8)
5.3.1.1.pseudo.26 Case report forms (E3 16.3)
5.3.1.1.pseudo.26.1 Site [site-id (O)]
5.3.1.1.pseudo.27 Available on request
5.3.1.1.pseudo.28 Data tabulation
5.3.1.1.pseudo.28.1 Data tabulation dataset legacy 
5.3.1.1.pseudo.28.2 Data tabulation dataset sdtm
5.3.1.1.pseudo.28.3 Data tabulation data definition
5.3.1.1.pseudo.29 Data listing dataset (E3 16.4)
5.3.1.1.pseudo.29.1 Data listing dataset
5.3.1.1.pseudo.29.2 Data listing data definition
5.3.1.1.pseudo.30 Analysis datasets
5.3.1.1.pseudo.30.1 Analysis dataset adam
5.3.1.1.pseudo.30.2 Analysis dataset legacy Analysis program
5.3.1.1.pseudo.30.3 Analysis data definition
5.3.1.1.pseudo.31 Annotated CRF
5.3.1.1.pseudo.32 ECG
5.3.1.1.pseudo.33 Image
5.3.1.1.pseudo.34 Subject profiles
5.3.1.1.pseudo.34.1 Site [site-id (O)]
5.3.1.1.pseudo.35 Safety report
5.3.1.1.pseudo.36 Assay validation
5.3.1.1.pseudo.37 Biomarkers
5.3.1.1.pseudo.38 Data monitoring review committees
5.3.1.1.pseudo.39 Device information
5.3.1.1.pseudo.40 Diagnostic tests
5.3.1.1.pseudo.41 Gene therapy
5.3.1.1.pseudo.42 Patient reported outcomes
5.3.1.1.pseudo.43 Pharmacodynamics
5.3.1.1.pseudo.44 Pharmacogenomics
5.3.1.1.pseudo.45 Pharmacokinetics
5.3.1.1.pseudo.46 Quality of life
5.3.1.1.pseudo.47 Stem cells
5.3.1.1.pseudo.48 Abuse liability
5.3.1.1.pseudo.49 Antibody
5.3.1.1.pseudo.50 Healthcare utilization
5.3.1.1.pseudo.51 Other data not specified
5.3.1.1.pseudo.52 PK PD relationship
5.3.1.1.pseudo.53 Specialty report
5.3.1.1.pseudo.54 Foreign clinical studies not under ind
5.3.1.2 Comparative BA and bioequivalence (BE) Study reports and related information 
5.3.1.2.pseudo [study id_study title (R)]
5.3.1.2.pseudo.1 [document type (R)]
5.3.1.2.pseudo.2 [see 5.3.1.1]
5.3.1.3 In Vitro - in Vivo correlation Study reports and related information 
5.3.1.3.pseudo [study id_study title (R)]
5.3.1.3.pseudo.1 [document type (R)]
5.3.1.3.pseudo.2 [see 5.3.1.1]
5.3.1.4 Reports of bioanalytical and analytical methods for human studies 
5.3.1.4.pseudo [study id_study title (R)]
5.3.1.4.pseudo.1 [document type (R)]
5.3.1.4.pseudo.2 [see 5.3.1.1]
5.3.2 Reports of studies pertinent to pharmacokinetics using human biomaterials
5.3.2.1 Plasma protein binding Study reports and related information 
5.3.2.1.pseudo [study id_study title (R)]
5.3.2.1.pseudo.1 [document type (R)]
5.3.2.1.pseudo.2 [see 5.3.1.1]
5.3.2.2 Reports of hepatic metabolism and drug interaction studies 
5.3.2.2.pseudo [study id_study title (R)]
5.3.2.2.pseudo.1 [document type (R)]
5.3.2.2.pseudo.2 [see 5.3.1.1]
5.3.2.3 Reports of studies using other human biomaterials 
5.3.2.3.pseudo [study id_study title (R)]
5.3.2.3.pseudo.1 [document type (R)]
5.3.2.3.pseudo.2 [see 5.3.1.1]
5.3.3 Reports of human pharmacokinetic (PK) studies
5.3.3.1 Healthy subject PK and initial tolerability Study reports and related information 
5.3.3.1.pseudo [study id_study title (R)]
5.3.3.1.pseudo.1 [document type (R)]
5.3.3.1.pseudo.2 [see 5.3.1.1]
5.3.3.2 Patient PK and initial tolerability Study reports and related information 
5.3.3.2.pseudo [study id_study title (R)]
5.3.3.2.pseudo.1 [document type (R)]
5.3.3.2.pseudo.2 [see 5.3.1.1]
5.3.3.3 Intrinsic factor PK Study reports and related information 
5.3.3.3.pseudo [study id_study title (R)]
5.3.3.3.pseudo.1 [document type (R)]
5.3.3.3.pseudo.2 [see 5.3.1.1]
5.3.3.4 Extrinsic factor Study reports and related information 
5.3.3.4.pseudo [study id_study title (R)]
5.3.3.4.pseudo.1 [document type (R)]
5.3.3.4.pseudo.2 [see 5.3.1.1]
5.3.3.5 Population PK Study reports and related information 
5.3.3.5.pseudo [study id_study title (R)]
5.3.3.5.pseudo.1 [document type (R)]
5.3.3.5.pseudo.2 [see 5.3.1.1]
5.3.4 Reports of human pharmacodynamic (PD) studies
5.3.4.1 Healthy subject PD and PK/PD Study reports and related information 
5.3.4.1.pseudo [study id_study title (R)]
5.3.4.1.pseudo.1 [document type (R)]
5.3.4.1.pseudo.2 [see 5.3.1.1]
5.3.4.2 Patient PD and PK/PD Study reports and related information 
5.3.4.2.pseudo [study id_study title (R)]
5.3.4.2.pseudo.1 [document type (R)]
5.3.4.2.pseudo.2 [see 5.3.1.1]
5.3.5 Reports of efficacy and safety studies [indication (R)]
5.3.5.1 Study reports and related information of controlled clinical studies pertinent to the claimed indication 
5.3.5.1.pseudo [study id_study title (R), type of control (R)]
5.3.5.1.pseudo.1 [document type (R)]
5.3.5.1.pseudo.2 [see 5.3.1.1]
5.3.5.2 Study reports and related information of uncontrolled clinical studies 
5.3.5.2.pseudo [study id_study title (R)]
5.3.5.2.pseudo.1 [document type (R)]
5.3.5.2.pseudo.2 [see 5.3.1.1]
5.3.5.3 Reports of analyses of data from more than one study
5.3.5.3.pseudo [study id_study title (R)] 
5.3.5.3.pseudo.01 [document type (R)]
5.3.5.3.pseudo.02 Integrated analysis of safety
5.3.5.3.pseudo.02.1 Iss
5.3.5.3.pseudo.02.2 Analysis datasets
5.3.5.3.pseudo.02.2.1 Analysis dataset adam
5.3.5.3.pseudo.02.2.2 Analysis dataset legacy
5.3.5.3.pseudo.02.2.3 Analysis program
5.3.5.3.pseudo.02.2.4 Analysis data definition
5.3.5.3.pseudo.03 Integrated analysis of efficacy
5.3.5.3.pseudo.03.1 Ise
5.3.5.3.pseudo.03.2 Analysis datasets
5.3.5.3.pseudo.03.2.1 Analysis dataset adam
5.3.5.3.pseudo.03.2.2 Analysis dataset legacy
5.3.5.3.pseudo.03.2.3 Analysis program
5.3.5.3.pseudo.03.2.4 Analysis data definition
5.3.5.4 Other Study reports and related information
5.3.5.4.pseudo [study id_study title (R)]
5.3.5.4.pseudo.01 [document type (R)]
5.3.5.4.pseudo.02 Antibacterial microbiology reports
5.3.5.4.pseudo.02.1 Antibacterial
5.3.5.4.pseudo.03 Special pathogens (e.g., fungi, parasites, mycobacteria) and
5.3.5.4.pseudo.04 immune modulator reports
5.3.5.4.pseudo.04.1 Special pathogen
5.3.5.4.pseudo.05 Antiviral reports
5.3.5.4.pseudo.05.1 Antiviral
5.3.5.4.pseudo.06 BIMO
5.3.5.4.pseudo.06.1 bimo
5.3.5.4.pseudo.07 Human Factor
5.3.5.4.pseudo.07.1 HF-validation-protocol
5.3.5.4.pseudo.07.2 HF-validation-report
5.3.5.4.pseudo.07.3 HF-validation-other
5.3.6 Reports of postmarketing experience
5.3.6.pseudo (This line is added by the software for displaying purpose.)
5.3.6.pseudo.01 Postmarketing periodic adverse event drug
5.3.6.pseudo.02 experience report description
5.4 Literature references